FDA Grants Priority Review for Roche's Enspryng in Thyroid Eye Disease
The FDA has granted priority review for Roche's Enspryng (satralizumab) for treating thyroid eye disease, based on positive phase III trial results.
Therapeutic Area
Therapeutic area intelligence for Thyroid Eye Disease with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Viridian Therapeutics is conducting a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of VRDN-003 in patients with Thyroid Eye Disease.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.